The influence of cellular origin on glioma pathogenesis remains elusive. We previously showed that mutations inactivating Rb and Pten and activating Kras transform astrocytes and induce tumorigenesis throughout the adult mouse brain. However, it remained unclear whether astrocyte subpopulations were susceptible to these mutations. We therefore used genetic lineage tracing and fate mapping in adult conditional, inducible genetically engineered mice to monitor transformation of glial fibrillary acidic protein (GFAP) and glutamate aspartate transporter (GLAST) astrocytes and immunofluorescence to monitor cellular composition of the tumor microenvironment over time. Because considerable regional heterogeneity exists among astrocytes, we also examined the influence of brain region on tumor growth. GFAP astrocyte transformation induced uniformly rapid, regionally independent tumor growth, but transformation of GLAST astrocytes induced slowly growing tumors with significant regional bias. Transformed GLAST astrocytes had reduced proliferative response in culture and in vivo and malignant progression was delayed in these tumors. Recruited glial cells, including proliferating astrocytes, oligodendrocyte progenitors and microglia, were the majority of GLAST, but not GFAP astrocyte-derived tumors and their abundance dynamically changed over time. These results suggest that intrinsic astrocyte heterogeneity, and perhaps regional brain microenvironment, significantly contributes to glioma pathogenesis.
INTRODUCTION
Glioblastoma (GBM) is the most common and biologically aggressive primary brain tumor and has a dismal survival of 12-15 months. Current standard of care includes surgical resection followed by concurrent fractionated radiation and chemotherapy with temozolomide (56, 57) . However, these treatments fail to prevent tumor recurrence. GBM continues to be diagnosed as a single disease entity based on histopathology, but these tumors display significant morphological, molecular, and biological heterogeneity. Indeed, comprehensive genomic profiling has identified multiple subtypes with distinct cellular composition, therapeutic responses, and clinical outcomes (46, 50, 61) . Defining the underlying sources of the extensive heterogeneity in GBM would facilitate improved classification and development of mechanism-based strategies to manage these fatal diseases.
Two models have been proposed to explain cancer heterogeneity (62) . In the mutation model, distinct tumor subtypes develop via transformation of a single cell type by different oncogenic mutations. Support for this model in GBM has been obtained through large scale sequencing studies of surgically resected human tumors. These studies have shown common mutations in G1/S cell cycle checkpoint, receptor tyrosine kinase/mitogen activated protein kinase/phosphoinositide 3-kinase (RTK/MAPK/PI3K), and TP53 "core GBM signaling pathway" genes (6, 8) . Genetically engineered mouse (GEM) models have become essential experimental tools for confirming the role of these mutations in driving tumorigenesis in the intact mammalian brain. Many, including lossof-function mutations in Cdkn2a, Nf1, Pten, or Trp53 tumor suppressor genes and activating mutations in Egfr, Kras, or Akt1 oncogenes, have been shown to produce gliomas when combined to transform cells of a single type: those expressing the glial fibrillary acidic protein (GFAP) (1, 4, 12, 13, 23, 52, 60, 70) .
In contrast, the cellular origin model proposes that tumor subtypes arise via transformation of different cell types. Evidence supporting the cellular origin model in GBM was first obtained through comparative transcriptome profiling, which showed that human GBM subtypes harbor transcriptomes similar to purified mouse astrocytes, neurons, oligodendrocyte progenitor cells (OPC) and neural stem cells (NSC) (61) . A variety of GEM models have shown that different mutations can transform each of these cells and induce gliomas. For example, mutations that inactivate RB family pocket proteins (12, 55, 67) , Cdkn2a (19, 23, 60) , Nf1 (29, 71) , Pten (12, 29, 55, 70) , or Trp53 (12, 16, 19, 29, 70, 71) and activate Hras (13, 16) , Kras (1, 22, 60) or Akt1 (22, 30) have been shown to transform terminally differentiated, GFAP 1 astrocytes (hereafter GFAP astrocytes). The combination of Trp53 deletion and Hras activation has been shown to transform neurons expressing Synapsin 1 (Syn1) (16) . Deletion of Cdkn2a (32), Nf1 (17, 34) , or Trp53 (17, 34) , overexpression of Pdgfb (33) , and activation of Kras (32, 33) or Akt1 (32, 33) has been shown to transform OPC expressing neural/glial antigen 2 (NG2, a proteoglycan encoded by Cspg4) or 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase (CNPase encoded by Cnp). Finally, deletion of Cdkn2a (19, 23, 60) , Nf1 (2), Pten (2, 19), or Trp53 (2, 23) and activation of Kras (22, 60) or Akt1 (22, 60) has been shown to transform NSC that express the intermediate filament protein nestin (encoded by Nes). These GEM models collectively demonstrate that gliomas can arise via transformation of multiple cell types through a variety of core GBM pathway mutations. They also suggest that the interaction between tumor initiating mutations and cellular origin may further contribute to GBM heterogeneity.
The most fundamental ramification of the cellular origin model of cancer heterogeneity is that the biological state of the initially transformed cell may profoundly influence tumor pathogenesis. Biologic factors intrinsic to the initially transformed cell include its ontogeny or developmental origin. Biological factors extrinsic to the cell include the cellular and biochemical milieu present in its local/regional microenvironment. These factors may be particularly important for glioma pathogenesis, especially for tumors originating from terminally differentiated or "mature" astrocytes (hereafter astrocytes), the most common, heterogeneous, and widely distributed glial cell in the mammalian brain.
Astrocytes are a diverse population of glial cells with distinct ontogenies and developmental origins (11) . They arise during embryonic to early postnatal development from precursor populations located in different regions of the brain (18, 65) . Astrocytes are produced during embryogenesis from stem-like radial glia in ventricular (VZ) and subventricular zones (SVZ). Maximal astrocyte production occurs perinatally (5) from intermediate progenitors in the VZ/SVZ (38, 47) , as well as from local GFAP astrocytes in other brain regions (18) . VZ/SVZ (54) and local astrocyte production decreases to low levels in the young adult brain (18) . Thus, adult astrocytes are terminally differentiated and essentially quiescent.
During the perinatal period, regional astrocyte diversity is generated in part through production from specific subsets of intermediate forebrain progenitors. Dorsal (Emx1 1 ), medial (Dbx-1 1 ), and intermediate (Nkx2.1 1 ) progenitors have been shown to produce astrocytes in the cortex (CTX), diencephalon (DI), and hypothalamus, respectively (59) . These distinct cellular ontogenies could potentially explain the region-specific transcriptome programs that have been documented in the adult mouse brain (3, 14, 68) , as well as region-specific expression of astrocyte markers, such as glutamate aspartate transporter (GLAST encoded by Slc1a3) and Kir4.1 (encoded by Kcnj10) (21, 48, 49, 65) . Differential expression of astrocyte markers has been utilized to develop GEM models that target transgene expression to astrocyte subpopulations (41, 59) . Whereas astrocytes expressing ALDH1L1 and to a lesser extent GFAP are abundant in most brain regions (7) , GLAST astrocyte expression levels are more regionally restricted (20, 48, 49, 53) . However, GEM glioma models developed to date have exclusively used the GFAP promoter to target oncogenic mutations to astrocytes (52) . Thus, it remains unclear whether astrocyte subpopulations are uniformly susceptible to transformation. One recent report showed regional differences in growth of cultured Nf1-null astrocytes harvested from various regions of the neonatal mouse brain (68) . However, it remains unclear whether intrinsic astrocyte heterogeneity impacts glioma pathogenesis in the intact, adult mammalian brain.
Conditional, inducible GEM models are ideally suited for experimentally addressing the mutation and cellular origin models of cancer heterogeneity. We have developed such models using mutations in the G1/S and RTK core GBM pathways in adult GFAP 1 brain cells (52, 55) . To disrupt the G1/S checkpoint, we inactivated all three members of the Rb family of pocket proteins using a single GFAP-driven transgene encoding the N-terminal 121 amino acids of SV40 large T antigen (T 121 , T) (67) . A conditional knock-in encoding constitutively active Kras (Kras G12D , R) and a conditional Pten knockout (Pten Del , P) were used to separately activate the two major effector arms of RTK signaling, MAPK and PI3K (8, 25, 58, 63) . We have shown that T 121 alone was sufficient for tumor initiation in adult mice and that the addition of Kras G12D and Pten Del facilitated progression to high grade disease (55) . However, it remained unclear whether subpopulations of adult astrocytes would respond similarly to their tumorigenic effects. To further explore this issue, we targeted TRP mutations to subpopulations of adult astrocytes using GFAP-CreER and GLAST-CreER and used genetic lineage tracing to monitor tumor growth and immunofluorescence-based fate mapping to map the fate of transformed cells over time. Here we demonstrate that TRP mutations transform GFAP astrocytes into rapidly growing tumors that are broadly distributed in multiple brain regions. In contrast, targeting these same mutations to the GLAST subpopulation produce slower growing tumor cells in culture, as well as slower growing tumors with regional differences, significant microenvironmental responses from local, proliferating glia, and delayed malignant progression in vivo. These results support the contribution to glioma pathogenesis of intrinsic biological factors governing astrocyte heterogeneity.
MATERIALS AND METHODS

Mice
Heterozygous TgGZT 121 (T) (67), Kras G12D1/lsl (R) (25) , Pten loxP (P) (58), GFAP-CreER (10), GLAST-CreER (26), and Rosa26-tdTomato (36) mice were maintained on a C57/Bl6 background. PCR genotyping was performed as previously described. Cre expression was induced in 3 month old adult mice by five daily intraperitoneal injections of 4-hydroxytamoxifen (Sigma-Aldrich, St Louis, MO) at 100 mg/kg. Induced mice were sacrificed 1, 3, 8 or 16 weeks after induction. Prior to sacrifice, mice were given 5 0 -ethynyl-2 0 -deoxyuridine (EdU) at 5 mg/kg via intraperitoneal injection 4 h before transcardial perfusion with 4% paraformaldehyde to label dividing cells. Brains were dissected and postfixed in 4% para-formaldehyde overnight at 48C. All data were obtained from three mice per cohort with two exceptions: competing causes of morbidity in TRP;GLAST-CreER;tdTomato mice, primarily large subcutaneous lesions, required euthanasia and limited the number analyzed at 8 (N 5 2) and 16 weeks (N 5 1).
Separate cohorts of TRP;GFAP-CreER (N 5 50) and TRP;GLAST-CreER (N 5 7) mice were aged to neurological morbidity and sacrificed upon development of lethargy, weight loss, deterioration in body condition, poor grooming, bulging skull, seizures, ataxia or paralysis. Survival was analyzed by Kaplan-Meier plots and compared using log-rank tests in GraphPad Prism (San Diego, CA, USA) as previously described (63) .
Focal tumor formation was induced in three month old TRP;tdTomato mice via stereotactic injection of 2 3 10 7 plaque forming units (1 mL) of Ad-GFAPCre (University of Iowa Gene Transfer Vector Core) into the olfactory bulb (OFB) (coordinates 4, 0.6, 2.5) or SVZ (coordinates 1, 1.3, 3.3 A,L,D). Brains were analyzed after four weeks using immunofluorescence. Animal studies were approved by and followed the euthanasia guidelines of the University of North Carolina Institutional Animal Care and Use Committee.
Cell culture
Primary GFAP
1 TRP astrocytes were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin as previously described (39, 63) . Cells were sorted into GLAST 1 and GLAST -subpopulations using a GLAST antibody (clone ACSA-1, Miltenyi Biotec, San Diego, CA, USA, catalog 130-098-804, 1:100) and a Beckman Coulter MoFlo XDP in the UNC Flow Cytometry Facility. Cells were sorted in PBS supplemented with 1 mM EDTA, 25 mM HEPES pH 7.0, 1% bovine serum albumin (BSA), and 1 mL/mL DNase and cultured as above.
To examine growth of cultured astrocyte subpopulations, 5000 cells per well were plated in quadruplicate in 96-well plates. Growth was assayed after 0-4 days using the CellTiter 96 AQueous Proliferation Assay (Promega, Fitchburg, WI, USA). Absorbance at 490 nm was determined on a Molecular Devices Emax plate reader (Chicago, IL, USA) equipped with SoftMax Pro 5 software. Relative growth was calculated as absorbance relative to day 0. Data (mean 6 SEM) were fit to a logarithmic equation to calculate doubling times that were compared using the extra-sum-ofsquares F test in GraphPad Prism.
Immunohistochemistry (IHC) and immunocytochemistry (ICC)
Fixed brains were embedded in 1% agarose (Promega) and 50 mm sagittal sections were cut using a Leica VT100S vibratome. Sections were permeabilized and blocked with 0.5% Triton X-100, 10% BSA, 5% normal goat serum, and 0.01 M glycine in PBS for 1 h. Sections were incubated in primary antibody overnight in 0.1% Triton X-100 in PBS. EdU was detected using a Click-It EdU imaging kit (Invitrogen, Grand Island, NY, USA) per manufacturer's instructions. Sections were washed and incubated for 4 h with secondary antibody diluted in 0.1% Triton X100 in PBS. Slides were counterstained with DAPI and cover-slipped using PermaFluor (Thermo Scientific, Waltham, MA, USA Cultured TRP cell subpopulations sorted based on GLAST expression were seeded on Nunc Lab-Tek II chamber slides (Thermo Scientific) coated with poly-D lysine (Sigma-Aldrich). EdU (10 mM) was added to each well 12 h prior to fixation with 4% para-formaldehyde for 10 minutes. Slides were then blocked with 1% BSA fraction V and 5% goat serum in PBS (SigmaAldrich) and incubated (30 minutes at 48C) with primary or secondary antibodies listed above and diluted in PBS with 0.05% Triton X100. EdU was detected a Click-It EdU imaging kit. Slides were counterstained with DAPI and coverslipped using PermaFluor.
Image analyses
For genetic lineage tracing and quantification of cells in situ, 3-5 random IHC images of the CTX, DI, brain stem (BS) and OFB (Supporting Information Figure S1 ) were taken from each of 2-3 sagittal sections per mouse. Four random ICC images were taken from each of four chamber wells. Images were obtained using LSM710 and LSM 780 confocal microscopes (Zeiss, Oberkochen, Germany) equipped with 203 objectives and ZEN 2012 software. The percentage of DAPI 1 cells expressing tdTomato or incorporating EdU was quantified using ImageJ and images panels arranged in Adobe Photoshop CS5 (San Jose, CA). The mean percent of tdTomato 1 or EdU 1 cells 6 s.e.m. from 24 to 36 images per brain region (IHC) and 16 images (ICC) per cell type was calculated.
For quantification of tumor growth rates, 4-5 random images of each brain region were taken from 2 to 3 sagittal sections per mouse. The mean percent of tdTomato 1 or EdU 1 cells 6 s.e.m. from 24 to 36 images was then calculated. Hyper-cellular areas with a twofold increase in average cellular density were apparent 8-16 weeks after induction. ImageJ was used to quantify the mean percent 6 s.e.m. of cortical cells expressing tdTomato or Ki-67 from 3 to 5 images of hyper-cellular and adjacent areas of diffuse tumor per mouse. ImageJ was also used to quantify proliferating (EdU 1 ), recruited (tdTomato -) glial cells that expressed the astrocyte marker BLBP, the microglial marker Iba1, or the oligodendrocyte progenitor marker PDGFRa. The mean percent 6 s.e.m. was then calculated from 4 to 8 images per brain region.
Histopathological evaluation
Brains were harvested, cut sagittally, immersion fixed in 10% neutral buffered formalin overnight, and stored in 70% ethanol prior to paraffin embedding. Formalin-fixed, paraffin embedded brains were cut on a rotary microtome in serial 4-5 lm sections, placed on glass slides, and stained with hematoxylin and eosin (H&E) on a Leica Microsystems Autostainer XL (Buffalo Grove, IL, USA). H&E stained slides were scanned on an Aperio ScanScope XT (Vista, CA, USA) using a 203 objective. The resulting svs files were imported into an Aperio eSlideManager web database. Histopathological analysis and grading was performed by CRM according to WHO 2007 criteria for human gliomas (35) .
Chromogenic IHC for SV40 T antigen, GFAP, BLBP, and Nestin was performed on a Bond fully-automated stainer (Leica, Norwell, MA, USA) as described (42) . Slides were deparaffinized in Bond dewax and hydrated in Bond wash solutions. Antigen retrieval was performed for 30 minutes at 1008C in Bond epitope retrieval solutions at pH 6.0 (GFAP, BLBP, Nestin) or 9.0 (SV40). Sections were incubated with primary antibodies described above for 1 h at 238C (SV40, 1:200; GFAP, 1:2000; BLBP, 1:500; Nestin, 1:250). Horseradish peroxidase and 3,3 0 -diaminobenzidine chromogen detection was performed using the Bond Polymer Refine Detection Kit with (SV40, Nestin) or without (GFAP, BLBP) a Dako EnVision 1 goat anti-mouse secondary antibody. Photomicrographs were taken on an Olympus BX41 microscope and DP70 digital camera (Center Valley, PA, USA).
Statistics
Data were analyzed using student's t-tests, one-way and two-way ANOVA with Tukey's correction for multiple comparisons, and non-linear and linear regression in GraphPad Prism 5. All comparisons were considered significant at a 5 0.05.
RESULTS
Adult GLAST astrocytes are a limited, regionally restricted subpopulation of GFAP astrocytes
We examined the regional distribution of GFAP and GLAST astrocytes in adult GFAP-and GLAST-CreER;tdTomato mouse brains using genetic lineage tracing and found that 4.5-6.1% and 0.3-4.4% of cells expressed tdTomato, respectively ( Figure 1A ). GFAP cells were uniformly distributed in the CTX, DI, BS and OFB. In contrast, GLAST cells were heterogeneously distributed and less abundant. Targeting efficiency differed between models, as brains stained for the astrocyte marker BLBP showed co-expression in 60% of GFAP and <40% of GLAST tdTomato 1 cells ( (Figure 1C,F) was extremely inefficient, as <0.3% of these cells expressed tdTomato in both models. Thus, recombination was >97% specific for BLBP 1 astrocytes in both models ( Figure  1D ,G).
GFAP is expressed in most astrocytes throughout the brain, except cortical gray matter (65) . In contrast, GLAST has been shown to be expressed in a subset of GFAP 1 astrocytes in vitro (45) . We have confirmed that few gray matter astrocytes express GFAP, but the vast majority (96.3%) of GLAST astrocytes coexpress GFAP in the areas analyzed (Supporting Information Figure S4) . We therefore conclude that GLAST astrocytes comprise a less abundant and more regionally restricted subpopulation of GFAP astrocytes in these models.
Cellular origin influences tumor growth
Multiple GBM mutations have been shown to transform astrocytes in GEM models (52) . We previously described one such model Figure 1 . GLAST astrocytes are less abundant and more regionally restricted than GFAP astrocytes. Genetic lineage tracing in GFAPCreER;tdTomato and GLAST-CreER;tdTomato mice sacrificed 1 week after induction shows significant brain region-specific differences between drivers in CTX, DI, and BS (*, P < 0.02), but not the OFB (P 5 0.7) (A). No regional differences were evident in astrocyte targeting efficiency in GFAPCreER;tdTomato mice (ANOVA P 5 0.8) (B). Cortical astrocyte targeting was more efficient (58.5 6 1.6%) than NeuN 1 neurons (0.2 6 0.1%),
IBA1
1 microglia (0.05 6 0.3%), and PDGFRa 1 oligodendrocyte progenitor cells (0.02 6 0.01%) in these mice (ANOVA P < 0.0001) (C). Moreover, targeting was specific to astrocytes, as 97.2% of the tdTomato 1 cell population co-expressed BLBP (D). In contrast, regional differences in astrocyte targeting efficiency were evident in GLAST-CreER;tdTomato mice (ANOVA P 5 0.02; *, Tukey's P < 0.05) (E). Cortical astrocyte targeting was more efficient (22.5 6 3.3%) than NeuN 1 neurons (0.09 6 0.01%), IBA1 1 microglia (0.03 6 0.01%), and PDGFRa 1 oligodendrocyte progenitor cells (0.02 6 0.01%) in these mice as well (ANOVA P 5 0.0001) (F). Like GFAP, GLAST targeting was specific to astrocytes, as 97.2% of the tdTomato 1 cell population co-expressed BLBP (G).
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International Society of Neuropathology using TRP mutations to transform adult GFAP astrocytes and showed that these mice develop lethal GBM after 4.4 months (55). However, it remained unclear whether brain region influenced tumor growth. All astrocyte-targeted glioma GEM models described to date have employed the GFAP promoter (12, 16, 52, 55) . Because this promoter targets a large and widely distributed population of astrocytes in adult mice, it remained unclear whether astrocyte subpopulations would also be susceptible to transformation. We therefore monitored regional tumor burden using lineage tracing in TRP;GFAP-and TRP;GLASTCreER;tdTomato mice to examine whether astrocyte subpopulations respond similarly to TRP mutations. In both models, tdTomato 1 tumor cells expressed the T 121 oncogene (>92%) and the vast majority (>97%) maintained BLBP expression. Tumor cells from both models also co-expressed the astrocyte markers GFAP and S100b (Supporting Information Figure S5 ). TRP mutations induced proliferation (EdU incorporation) and increased tumor burden in all brain regions after 3-16 weeks, but the magnitude of both differed markedly between GFAP versus GLAST astrocytes (Supporting Information Figure S6 ). Hyper-cellular rims of tdTomato 1 tumor cells around neurons (perineuronal satellitosis, PNS), a widely recognized growth pattern in human gliomas (40) , also developed in these mice. PNS composed of tdTomato 1 tumor cells co-expressing GFAP and BLBP increased over time in both models. However, PNS development was slower and less pronounced in GLASTderived tumors (Supporting Information Figure S7 ). We therefore conclude that cellular origin influences astrocyte-derived tumor growth.
Brain region may influence growth of GLAST, but not GFAP astrocyte-derived tumors
To directly compare the growth rate of GFAP and GLAST astrocyte-derived tumors and to examine the effects of brain region, we quantified the density of tdTomato 1 cells in different regions over time in mice with (3 weeks) and without (1 week) induced TRP mutations. Tumor growth from GFAP astrocytes was rapid and independent of brain region (Figure 2A ). In contrast, GLAST astrocyte tumor growth was slower and significantly influenced by brain region; growth was relatively rapid in OFB and slow in BS (Figure 2B-D) . Moreover, GLAST ( Figure 2F ), but not GFAP astrocyte-derived ( Figure 2E ) tumors showed significant regional differences in proliferation rates ( Figure 2G,H) . These results suggest that astrocyte subpopulations respond differently to identical tumor initiating mutations and that regional microenvironment may influence tumor growth.
NSC in the SVZ express both GFAP (56%) and GLAST (6%) and have the ability to differentiate into neuroblasts that migrate through the rostral migratory stream to become OFB interneurons (Supporting Information Figure S6) . Thus, the migratory potential of transformed NSC progeny could theoretically complicate our regional astrocyte proliferation analyses. To explore whether transformed SVZ NSC contributed to tumor burden in the regions analyzed (Supporting Information Figure S1 ), we focally induced recombination with Ad-GFAPCre in either the SVZ or OFB of TRP;tdTomato mice. After four weeks, OFB injections produced focal tdTomato 1 ;T 1 121 tumors in the OFB ( Figure 3A ) that failed to migrate to other brain regions ( Figure 3B ). Likewise, viral Figure 2 . Growth is slower and differs by brain region in TRP-induced tumors derived from GLAST versus GFAP astrocytes. Quantification of tdTomato (A, B) and EdU (E, F) positive cells from GFAPCreER;tdTomato (A, E) and GLAST-CreER;tdTomato (B, F) mice sacrificed 1 week after induction show that tumors grow and proliferate more slowly upon induction of TRP mutations over 3-16 weeks in GLAST versus GFAP astrocytes. Tumors derived from GLAST (ANOVA P 5 0.01), but not GFAP (ANOVA P 5 0.6) astrocytes showed regional differences in tdTomato growth rates (C). Data from C are regraphed in D to highlight the significantly increased tdTomato growth rate of GFAP versus GLAST derived tumors. Regional differences in proliferation rates (EdU incorporation) were significant in tumors derived from both GLAST (ANOVA P < 0.0001) and GFAP astrocytes (ANOVA P 5 0.04) (G). Data from G are regraphed in H to show that GFAP-derived tumor proliferation rates are significantly higher than GLAST-derived tumors. Significant regional differences in growth (G) and proliferation rates between drivers existed (P < 0.03) (H). Pairwise comparisons with P < 0.05 are indicated (*).
injections in the SVZ produced tumors in the periventricular parenchyma and striatum ( Figure 3C ) that did not migrate to the analyzed brain regions ( Figure 3D ). These results demonstrate that TRP mutations transform NSC to produce tumors, but that NSCderived tumor cells fail to migrate to other brain regions in this model system.
Cellular origin influences malignant progression
While regional microenvironment appeared to influence GLASTderived tumor growth (Figure 2) , it remained unclear whether intraregional differences would also be evident. We therefore monitored intraregional heterogeneity by imaging the entire cortex, the largest anatomical region of the brain. Tumor growth from both GFAP and GLAST (Supporting Information Figure S8 ) astrocytes was uniform over their initial growth phases (less than 3 and 8 weeks, respectively). However, significant intraregional heterogeneity appeared later in the course of tumor progression and multiple hyper-cellular tumor foci developed in both models (Supporting Information Figure S8C ,G).
We have previously found that high grade astrocytomas in the GFAP-driven TRP model acquire stochastic mutations during malignant progression, suggesting that clonal evolution may drive their heterogeneous proliferative response (55) . To further explore this, we stained tumors from GFAP and GLAST mice at 8 and 16 weeks after induction for Ki-67 to mark proliferating cells ( Figure  4A,B) . These analyses identified hyper-cellular tumor foci with 5-10 fold higher proliferation compared to adjacent areas of diffuse tumor ( Figure 4C,D) . Due to this intra-cortical heterogeneity, we quantified diffuse tumor, hyper-cellular foci, and total tumor burden separately at later time points. These analyses showed that initial growth of GFAP tumors was significantly higher than GLAST tumors and that hyper-cellular tumor foci emerged earlier ( Figure  4E ). These results suggest that GFAP and GLAST astrocytes have inherently distinct proliferative responses to identical TRP mutations. However, tumors grew at similar rates after hyper-cellular foci developed, suggesting that the proliferative response to mutations acquired during malignant progression was similar in both models.
GLAST mice survived significantly longer than GFAP mice when aged to morbidity, but their survival was limited by comorbid development of subcutaneous masses requiring euthanasia ( Figure 4F ). Histological analyses showed that GFAP mice died from large anaplastic astrocytomas (WHO grade III) or GBM (WHO grade IV) (55), while GLAST mice died with smaller diffuse astrocytomas (WHO grade II). Chromogenic IHC confirmed expression of T 121 and the astrocytic markers GFAP and BLBP (Supporting Information Figures S5 and S6 ) and also showed that tumors gained expression of the NSC marker nestin (Supporting Information Figure S9 ).
To examine whether TRP-mutated GLAST astrocytes have intrinsically distinct growth characteristics, we purified cultured, GFAP 1 TRP astrocytes into subpopulations by GLAST flow sorting ( Figure 4I ). Immunofluorescence analyses confirmed differential GLAST expression ( Figure 4G,H) . GLAST 1 TRP astrocytes . TRP tumors progress more slowly in GLAST versus GFAP astrocytes. Frequent hyper-cellular (HC, blue boxes) tumor foci (tdTomato, red) were evident in TRP;GFAP-CreER;tdTomato mice sacrificed 8 weeks after induction (A). In contrast, occasional hyper-cellular foci were only evident 16 weeks after induction in TRP;GLAST-CreER;tdTomato mice (B). HC areas were 5.2-fold more proliferative (student's t P 5 0.0001) than adjacent areas of diffuse tumor (red boxes) and 57.7% of these cells (Ki-67, green) were proliferating in GFAP mice (C). A similar increase in proliferation (11.2 fold, students' t P < 0.0001) and Ki-67 1 cell density (46.4%) was evident in GLAST mice (D). Despite induction by the same oncogenic TRP mutations, diffuse and total tumor growth was slower in GLAST than GFAP astrocytes (P < 0.0001). Growth rates were similar after HC foci developed (P 5 0.2), but these appeared later in the course of GLAST tumor progression (E). GLAST mice survived significantly longer than GFAP mice (log-rank, P 5 0.02). The GLST 1 (G) and GLAST 2 (H) subpopulations of cultured GFAP 1 TRP cells were purified by flow sorting (I) and differential GLAST expression was confirmed by ICC (GH). GLAST 1 cell S-phase fraction (EdU 1 ) was significantly less than their GLAST 2 counterparts (J, *P 5 0.0002) and their growth rate was significantly slower (K, doubling time 1.2 versus 0.9 days, P < 0.0001). Scale bars 100 mm (A, B), 50 mm (G, H).
harbored a lower S-phase fraction ( Figure 4J ) and grew slower ( Figure 4K ) than their GLAST -counterparts. These results suggest that the slower growth of GLAST-derived tumors in vivo is due to intrinsically distinct proliferative responses to identical TRP mutations.
Recruited cells are abundant in GLAST astrocyte-derived tumors
Nearly all transformed GFAP (Supporting Information Figure  S5A ) and GLAST astrocytes (Supporting Information Figure S5E ; Figure 5A ) co-expressed both tdTomato and T 121 and a subpopulation proliferated (Supporting Information Figure S6 ; Figure 2 ). While a subpopulation (20%) of EdU 1 cells lacked both tdTomato and T 121 in the GFAP model (S10AEF), a substantial number of these cells were identified in the GLAST model ( Figure 5B ), suggesting that these cells were recruited. To further explore the identity of proliferating cells, we stained GLAST and GFAP tumors with BLBP, PDGFRa, and Iba1 to identify astrocytes, OPC, and microglia within the tumor microenvironment ( Figure S10E ). Recruited astrocytes increased over time, but microglia and OPC decreased in GLAST tumors ( Figure 5I ). In contrast, proliferating, recruited astrocytes remained constant and there were minimal proliferating microglia and OPC in GFAP tumors (Supporting Information Figure S10F) . Proliferating glial cells differed markedly in GFAP-versus GLAST-derived tumors, both for tdTomato 1 tumor cells and tdTomato 2 recruited astrocytes and OPC (Supporting Information Figure S11 ). These results suggest that transformation of GLAST astrocytes induces a heterogeneous cellular response and that the composition of proliferating, recruited glia in the tumor microenvironment dynamically changes over time.
TRP mutations induce expression of the NSC marker nestin in tdTomato 1 tumor cells
We have shown that TRP mutations induce a primitive, proneural GBM-like gene expression state in cultured murine astrocytes (63) . We subsequently found that cultured TRP astrocytes acquire the functional properties of NSC in vitro and cancer stem cells in vivo (51). These results suggest that TRP mutations induce astrocyte dedifferentiation. To explore whether these mutations induce NSC marker expression in tumors induced in situ, we fate mapped tdTomato 1 tumor cells in GFAP and GLAST mice. In the absence of oncogenic mutations, both GFAP ( Figure 6A ) and GLAST (Figure 6F ) astrocytes lack the intermediate filament protein nestin, an established marker of NSC. In contrast, TRP mutations induced nestin expression in cortical tumors derived from GFAP ( Figure  6B ), and to a lesser extent, GLAST astrocytes ( Figure 6G ). These cells co-expressed tdTomato and BLBP and were more frequent and rapidly dividing in GFAP versus GLAST tumors (Figures 6C-E, H-K) These results support the notion that TRP mutations induce astrocyte dedifferentiation in situ and that slower growth of GLAST 1 tumors could be due to less efficient dedifferentiation.
DISCUSSION
Targeting astrocyte subpopulations based on expression of the established markers GFAP and GLAST yielded biologically distinct growth patterns when these cells were transformed with identical oncogenic mutations. Transformed GFAP astrocytes produced anaplastic astrocytomas (WHO grade III) that lacked a significant proliferating, recruited glial component, grew uniformly in all brain regions, and rapidly underwent malignant progression. In contrast, transformed GLAST astrocytes formed slowly growing low-grade astrocytomas whose growth differed by brain region. The more indolent growth of TRP-transformed GLAST 1 astrocytes was confirmed in vitro. GLAST derived tumors showed a significant proliferating, recruited glial component and underwent more gradual malignant progression. These results suggest that astrocyte subpopulations uniquely respond to the pro-proliferative signals of oncogenic TRP mutations. Further work is required to determine whether these distinct proliferative responses occur with other common glioma mutations. A model summarizing the effects of astrocyte heterogeneity on glioma pathogenesis and the microenvironmental differences between these models are shown in Figure 7 .
One possible explanation for the faster growth observed in GFAP astrocyte-derived tumors was the greater initial frequency of these cells in the adult brain. GFAP astrocytes constituted approximately 4-6% of cells in multiple brain regions ( Figure 1A ). In contrast, GLAST astrocytes represented a smaller and more regionally restricted subpopulation (0.3-4%, Figure 1A) . Of the latter, only those that co-expressed GFAP could be transformed, because T 121 transgene expression from the GFAP promoter is required for astrocyte transformation in these mice (55) . However, the difference in initial target cell density is unlikely to be the primary factor contributing to differential tumor growth rates. For example, GLAST and GFAP targeted similar numbers of OFB cells ( Figure 1A) . However, growth and proliferation rates of OFB tumors differed markedly in GFAP versus GLAST mice (Figure 2) . Moreover, growth and proliferation of the GLAST 1 subpopulation of TRPtransformed, GFAP 1 astrocytes ( Figure 4I ) was significantly slower than their GLAST -counterparts in culture ( Figure 4J ,K). This suggests that intrinsic differences in the cell of origin likely influenced tumor growth. One such factor could be that their cellautonomous mitogenic signaling networks could impart differential susceptibility to particular mutations. This concept is supported by previous studies showing that regional astrocyte subpopulations differentially express tumor suppressor genes such as Nf1 and have distinct proliferative responses to its deletion (68) . A second intrinsic factor could be the ability to dedifferentiate into a more primitive functional state. This concept is supported by the quantitative difference in nestin expression between the two models here (Figure 6) . Future work will be required to further explore this possibility.
We confirmed that SVZ NSC express both GFAP and GLAST (Supporting Information Figure S6 ). The migratory potential of their TRP-mutated progeny could theoretically complicate our regional analyses. However, genetic lineage tracing confirmed that the GFAP and GLAST drivers used here target BLBP 1 astrocytes with >97% specificity in the brain regions analyzed (Figure 1 ), but target SVZ NSC less efficiently (56% and 6%, respectively). Moreover, we found that focal transformation of the more abundant GFAP 1 population of NSC produced tumors only near the SVZ and striatum and that these tumor cells did not migrate outside these regions (Figure 3 ). In contrast, focal transformation of OFB astrocytes only produced OFB tumors. These results suggest that local astrocytes, not other transformed glia or NSC, are the source of tumor in the brain regions analyzed.
GFAP astrocyte-derived tumors underwent rapid growth and malignant progression, while GLAST-derived tumors showed more indolent growth and delayed progression ( Figure 4E ). These growth patterns mirror that of primary and secondary GBM in humans. Primary GBM have a clinically silent, pre-GBM growth phase and are thus thought to arise de novo. In contrast, secondary GBM arise from a documented low grade precursor and feature a more protracted clinical course (44) . Distinct genetic and epigenetic differences (EGFR and PTEN mutations in the former; IDH1/2 and TP53 mutations and the CpG island methylation phenotype (G-CIMP) in the latter) has strengthened the biological difference between these two clinical entities (6, 9, 43, 44) . Though their genetic differences are clearly established, it remains unclear how cellular origin might affect their growth patterns. We have argued that the GFAP model used here closely resembles primary GBM due to its rapid tumor growth and lack of IDH mutations (55) . We have shown that these tumors stochastically acquire secondary mutations, such as homozygous Pten deletions, that likely potentiate their progression (55) . In contrast, the GLAST model produces tumors with a protracted proliferative phase and delayed malignant progression, a growth pattern more similar to secondary GBM. We are currently exploring whether these tumors acquire alterations common in secondary GBM and whether these could be responsible for driving tumor expansion and malignant progression in this model system (Figures 4 and 7) .
Tumor heterogeneity may be influenced by the local glial microenvironment, which is composed of astrocytes, oligodendrocytes, and microglia. Glial cell populations show transcriptome variability based on brain region, which may reflect their distinct ontogenies (27) . It has long been known that the cellular composition of gliomas consists of a complex mixture of transformed cells, as well as recruited glia. In fact, recruited cells may constitute a majority within a given tumor (15) . Recruited glia have also been shown to promote tumor invasion and neovascularization, disrupt the blood brain barrier, and create a symbiotic microenvironment that promotes tumor growth (24, 30, 37, 64, 69) . Therefore, it logically follows that regional heterogeneity in the brain microenvironment may impact tumor pathogenesis. In contrast to the GFAP model, 64-80% of proliferating cells in the GLAST model were recruited glia ( Figure 5 ; Supporting Information Figures S10 and S11) . Therefore, this model may provide a unique opportunity to examine the contributions of recruited glia to tumor growth in future studies. Extensive recruited glia proliferation suggests paracrine communication between these and tdTomato 1 tumor cells within the tumor microenvironment, but the signaling mechanisms that mediate these effects remain to be defined. Recruited cells have been previously found in mouse models of platelet derived growth factor (PDGF)-driven tumors derived from PDGFRa 1 OPC (15, 31) . We have extended these findings by identifying recruited glia in tumors of astrocyte origin ( Figure  5 ), suggesting that glial recruitment is a stereotypical response to cellular transformation in the brain. While the cellular identity and time course of recruited cells were not examined in the PDGF model, we found that astrocytes, OPC, and microglia are all present within the GLAST tumor microenvironment and their abundance varies over time. We are currently exploring whether these cells become transformed by stochastic oncogenic mutations and the mechanisms through which they contribute to astrocyte-derived tumor growth.
Cells with stem-like properties have been identified in human GBM and may be responsible for treatment resistance and tumor recurrence (66) . Identification of these cells currently relies on immunostaining with stem cell markers, such as CD133 and nestin. However, our data ( Figure 6 ) and the work of other groups has shown that the differentiation state of tumor cells is dynamic. Thus, in contrast to the normal unidirectional lineage hierarchy in the normal brain, cancer cell lineage relationships are plastic. We have previously shown that transformation of cultured astrocytes by TRP mutations induces a primitive transcriptome state in vitro (63) . We have also found that TRP astrocytes acquire the functional properties of NSC in vitro and cancer stem cells in vivo (51) . Here, we show that TRP mutations induce the expression of the primitive maker nestin in situ ( Figure 6 ). Together, these results suggest that TRP mutations induce astrocyte dedifferentiation. Similar results have been found in astrocytes transformed by Cdkn2a, Egfr, Nf1, and Trp53 mutations, suggesting that astrocyte dedifferentiation may be a stereotypical response to oncogenic mutations (4, 16) . The opposite has been found in embryonic NSC with Nf1 and Trp53 deletion mutations, where transformed OPC drove tumor growth, suggesting that partial differentiation was required for NSC transformation (34) . Thus, either dedifferentiation or partial terminal differentiation may be required for oncogenic transformation in certain cellular and mutational contexts. As such, the mutated cell may differ from the transformed cell type that actually drives tumor growth. These dynamic changes in differentiation state of cancer cells complicate efforts to identify tumor cells of origin by comparing their expression of cellular markers to purified brain cells, as we have described for human gliomas (9, 61) . In contrast, the genetic lineage tracing and fate mapping techniques used here permit unambiguous identification of the tumor cell of origin and its impact on disease pathogenesis. Using these techniques, we found that GFAP and GLAST astrocytes can serve as a cell of origin for GBM, though the kinetics of growth and progression differed between these two subpopulations. Previously, we used lineage tracing to longitudinally monitor the growth kinetics of NG2
1 OPC transformed by Nf1 and Trp53 deletions (17) . In this mutational context, OPC proliferation peaks after initial transformation, then enters a sustained period of quiescence (17) . In contrast, TRP mutations induced sustained proliferation and eventual clonal tumor outgrowth in both GFAP and GLAST astrocyte models. These divergent growth characteristics suggest that cellular origin has a significant impact on tumor growth and that astrocyte subpopulations may have inherently different responses to particular oncogenic mutations. Indeed, cellular origin has recently been shown to be a key contributor to tumor heterogeneity in Pik3ca-driven mammary tumors (28) . To further probe the influence of cellular origin on glioma pathogenesis, we are currently investigating whether transformation of astrocytes and OPC with identical mutations induces similarly divergent patterns of tumor growth. 
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Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Figure S1 . Analyzed brain regions. Abundant tumor-containing brain regions included the CTX (red), DI (dark blue), BS (green), and OFB (purple) were analyzed. Areas producing less tumor were excluded, including the corpus callosum (CC, light blue) and striatum (STR, yellow). Figure S2 . GFAP-CreER targets astrocytes and not neurons in multiple brain regions. Genetic lineage tracing in GFAPCreER;tdTomato mice sacrificed 1 week after induction (Fig. 1 Figure S3 . GLAST-CreER targets astrocytes and not neurons in multiple brain regions. Genetic lineage tracing in GLASTCreER;tdTomato mice sacrificed 1 week after induction (Fig. 1) shows recombination-mediated expression of tdTomato in CTX, DI, BS, and OFB astrocytes as defined by their stellate morphology and co-expression of BLBP (A). Minimal tdTomato 1 neurons (0.2 6 0.1% of DAPI 1 cells), defined by their cellular morphology and co-expression of NeuN, were evident (B). Scale bar 10 mm. Figure S4 . GLAST-CreER targets GFAP 1 astrocytes in multiple brain regions. Over 96% of white matter (WM), DI, BS, and OFB astrocytes, defined by stellate morphology and co-expression of glial fibrillary acid protein (GFAP), expressed tdTomato in GLASTCreER;tdTomato mice sacrificed 1 week after induction. Few tdTomato 1 astrocytes in the grey matter (GM) co-expressed GFAP. The percentage of tdTomato 1 ;GFAP 1 cells in each region is indicated. Scale bar 10 mm. Figure S5 . GFAP and GLAST-driven TRP tumor cells retain expression of astrocytic markers. Three weeks after induction of TRP;GFAP-CreER;tdTomato mice, TRP-transformed cortical GFAP 1 astrocytes co-express tdTomato and T 121 (98.3 6 1.3%, A) and retain expression of the astrocytic markers BLBP (99.3 6 0.3%) (B), GFAP (C), and S100b (D). Likewise, transformed cortical GLAST 1 astrocytes in TRP;GLAST-CreER;tdTomato mice co-express tdTomato and T 121 (91.8 6 2.9%, E) and retain their expression of BLBP (96.8 6 2.9%) (F), GFAP (G), and S100b (H). Scale bar 10 mm. Figure S6 . TRP mutations induce proliferation of GFAP and GLAST astrocytes in multiple brain regions. GFAP cells (56 6 1.7%) in the subventricular zone (SVZ) express tdTomato (red), endogenously proliferate, and incorporate EdU (green) in GFAP-CreER;tdTomato mice sacrificed 1 week after induction. In contrast, GFAP astrocytes in the CTX, DI, BS, OFB express tdTomato, but do not proliferate, and fail to incorporate EdU in the absence of oncogenic mutations. However, TRP mutations induce progressive increases in GFAP astrocyte proliferation throughout the brains of TRP;GFAP-CreER;tdTomato mice sacrificed 3 and 8 weeks after induction (A). GLAST cells (5.8 6 0.6%) in the SVZ express tdTomato, endogenously proliferate, and incorporate EdU in GLAST-CreER;tdTomato mice sacrificed 1 week after induction. In contrast, GLAST astrocytes in the CTX, DI, BS, and OFB express tdTomato, but do not proliferate, and fail to incorporate EdU in the absence of oncogenic mutations. However, TRP mutations induce progressive increases in GLAST astrocyte proliferation (incorporation of EdU) throughout the brains of TRP;GLASTCreER;tdTomato mice sacrificed 3, 8, and 16 weeks after induction (B). Driver, TRP status, and sacrifice time point after induction are indicated. Nuclei were counterstained with DAPI (blue). Scale bar 10 mm. Figure S7 . Astrocytic perineuronal satellites increase over time in GFAP and GLAST-driven TRP tumors. Perineuronal satellites (PNS) composed of tdTomato 1 (red) tumor cells surrounding NeuN 1 (green) cortical neurons increased over time after induction of TRP mutations in GFAP-CreER;tdTomato mice (A). In contrast, perineuronal satellite development in GLAST-CreER;tdTomato mice was delayed and less frequent (BC). TRP status and sacrifice time point after induction are indicated. Tumors induced in both TRP;GFAP-CreER;tdTomato (DE) and TRP;GLAST-CreER;tdTomato (FG) mice display perineuronal satellites that co-stain with the astrocyte markers GFAP (DF) and BLBP (EG). Nuclei were counterstained with DAPI (blue). Scale bars 10 mm. Figure S8 . Cortical GFAP and GLAST-driven TRP tumor burden increases over time. Compared to GFAP-CreER;tdTomato mice sacrificed 1 week after induction (A), a time-dependent increase in tumor burden (tdTomato, red) was evident throughout the cortex of TRP;GFAP-CreER;tdTomato mice sacrificed after 3 (B) and 8 (C) weeks. Compared to GLAST-CreER;tdTomato mice sacrificed 1 week after induction (D), a timedependent increase in cortical tumor burden was evident in TRP;GLAST-CreER;tdTomato sacrificed after 3 (E), 8 (F), and 16 (G) weeks. Tumors became more heterogeneously distributed after 8 weeks (C) in GFAP and 16 weeks (G) in GLAST mice due to emergence of hyper-cellular foci (Fig. 4) . Nuclei were counterstained with DAPI (blue). Orientation: C, caudal; D, dorsal; R, rostral; V, ventral. Scale bars 1 mm. Figure S9 . GFAP and GLAST-driven TRP tumor cells retain expression of astrocytic markers and express the stem cell marker nestin. Anaplastic astrocytoma (WHO grade III) and diffuse astrocytoma (WHO grade II) tumors arose in the OFB (A-E) three months after induction of TRP mutations in TRP;GFAP-CreER;tdTomato and TRP;GLAST-CreER;tdTomato mice, respectively (A). Black arrowheads indicate mitoses in the former. Diffuse astrocytoma burden was lower in the CTX of both models (F-J) at the same time point (F). In contrast to wild-type OFB and CTX, tumor cells expressed T 121 (BG) retained expression of the astrocyte markers GFAP (CH) and BLBP (DI), and gained expression of stem cell markers such as nestin (EJ), particularly in GFAP mice. Scale bars 20 mm. Figure S11 . The microenvironment of GLAST-and GFAPderived tumors harbor distinct proliferating, recruited glial cell populations. TRP mutations induced significantly more proliferation (EdU 1 ) in GFAP than GLAST-derived tumor cells (P0.007; A). In contrast, GLAST-derived tumors harbored more proliferating, recruited astrocytes (P0.002; B), OPC (P0.02; C), and microglia (P0.3; D).
